Get the Stockscreener App
230.20
0.59%
1.33
After Hours:
230.95
0.75
+0.33%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $230.20, with a volume of 464.30K.
It is up +0.59% in the last 24 hours and down -0.26% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$228.87
Open:
$228.15
24h Volume:
464.30K
Relative Volume:
0.43
Market Cap:
$33.54B
Revenue:
$5.40B
Net Income/Loss:
$1.49B
P/E Ratio:
22.75
EPS:
10.1168
Net Cash Flow:
$1.78B
1W Performance:
+2.36%
1M Performance:
-0.26%
6M Performance:
-15.67%
1Y Performance:
+7.59%
1-Day Range:
$226.92
$230.34
1-Week Range:
$222.35
$234.91
52-Week Range:
$202.00
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
230.20 | 33.34B | 5.40B | 1.49B | 1.78B | 10.12 |
ISRG
Intuitive Surgical Inc
|
458.95 | 160.05B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
155.37 | 43.87B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
79.74 | 38.02B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
47.22 | 37.01B | 28.43B | 1.16B | 1.26B | 1.4457 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Trade Ideas — LSX:935168 - TradingView — Track All Markets
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
ResMed Faces Shifting Market Signals in Healthcare Space - Kalkine Media
ResMed (NYSE:RMD) CEO Michael Farrell Sells 4,991 Shares - MarketBeat
Citigroup Issues Pessimistic Forecast for ResMed (NYSE:RMD) Stock Price - MarketBeat
Resmed CEO Farrell sells $1.12 million in stock - Investing.com
Resmed CEO Farrell sells $1.12 million in stock By Investing.com - Investing.com Australia
ResMed (RMD) CEO Farrell sells 4,991 shares after option exercise - Stock Titan
ResMed Insider Selling Raises Questions On Management Conviction And Valuation - Sahm
ResMed Inc. stock rises Wednesday, still underperforms market - MarketWatch
ResMed, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
Citigroup Adjusts Price Target on ResMed to $340 From $345, Maintains Buy Rating - marketscreener.com
ResMed Inc. $RMD Shares Sold by Pacific Point Advisors LLC - MarketBeat
ResMed CEO Michael Farrell Plans Additional Insider Sale Under Rule 144 - TipRanks
Affiliate plans sale of 4,991 RMD shares via Fidelity (NYSE: RMD) - Stock Titan
Robinhood Asset Management Boosts ResMed Stake - National Today
Sleep Apnea Devices Market to Reach Strong Growth Through 2033 - openPR.com
ResMed Adjusts CDI and Share Balances Amid Transfers, Equity Issuance and Buybacks - TipRanks
ResMed Director Peter Farrell Plans Further Insider Share Sale Under Rule 144 - TipRanks
4,837 Shares in ResMed Inc. $RMD Acquired by Runnymede Capital Advisors Inc. - MarketBeat
Wealth Enhancement Advisory Services LLC Has $1.66 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Element Squared LLC Buys Shares of 6,067 ResMed Inc. $RMD - marketbeat.com
Aberdeen Group Reduces Stake in ResMed Inc. - National Today
Aberdeen Group plc Sells 37,737 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Brett Sandercock Sells Shares of ResMed Inc (RMD) - GuruFocus
RESMED INC. R (RME.MU) Q1 FY2025 earnings call transcript - Yahoo Finance
Resmed CFO Sandercock sells $224k in stock By Investing.com - Investing.com South Africa
Resmed CFO Sandercock sells $224k in stock - Investing.com
ResMed (RMD) CFO Sandercock sells 1,000 shares in open market trade - Stock Titan
J. Safra Sarasin Holding AG Sells 10,794 Shares of ResMed Inc. $RMD - marketbeat.com
Spire Wealth Management Cuts Stock Holdings in ResMed Inc. $RMD - marketbeat.com
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
ResMed Inc. (RMD) stock price, news, quote and history - Yahoo Finance UK
ResMed Inc. (RMD.AX) stock price, news, quote and history - Yahoo Finance Singapore
Insider Selling: ResMed (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat
ResMed Inc. (RMD) latest stock news and headlines - Yahoo Finance Singapore
Resmed director Farrell sells $450,000 in stock By Investing.com - Investing.com India
Resmed director Farrell sells $450,000 in stock - investing.com
Resmed Insider Sold Shares Worth $450,000, According to a Recent SEC Filing - marketscreener.com
ResMed (NYSE: RMD) director sells 2,000 shares under Rule 10b5-1 plan - Stock Titan
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
Peter C. Farrell (RMD) sells 6,000 shares via Rule 144 notices (NYSE: RMD) - Stock Titan
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026 - The Manila Times
Resmed to post quarterly results after market close on April 30 - Stock Titan
Affiliate proposes three 1,000-share sales for RMD (NYSE: RMD) — broker listed - Stock Titan
ResMed Inc. stock rises Tuesday, still underperforms market - MarketWatch
Is It Time To Revisit ResMed (RMD) After Recent Share Price Weakness? - Yahoo Finance
ResMed back on the Buy List - intelligentinvestor.com.au
ResMed Earnings Preview: What to Expect - Yahoo Finance
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):